These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 32632925)
21. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. Kroiss SJ; Famulare M; Lyons H; McCarthy KA; Mercer LD; Chabot-Couture G Vaccine; 2017 Oct; 35(42):5674-5681. PubMed ID: 28890193 [TBL] [Abstract][Full Text] [Related]
22. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. Kalkowska DA; Thompson KM Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841 [TBL] [Abstract][Full Text] [Related]
23. Potential Future Use, Costs, and Value of Poliovirus Vaccines. Thompson KM; Kalkowska DA Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244 [TBL] [Abstract][Full Text] [Related]
24. Polio endgame: the global switch from tOPV to bOPV. Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187 [TBL] [Abstract][Full Text] [Related]
25. An economic analysis of poliovirus risk management policy options for 2013-2052. Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632 [TBL] [Abstract][Full Text] [Related]
26. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638 [TBL] [Abstract][Full Text] [Related]
27. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective. Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179 [TBL] [Abstract][Full Text] [Related]
28. The risk of type 2 oral polio vaccine use in post-cessation outbreak response. McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220 [TBL] [Abstract][Full Text] [Related]
29. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine. Blake IM; Pons-Salort M; Molodecky NA; Diop OM; Chenoweth P; Bandyopadhyay AS; Zaffran M; Sutter RW; Grassly NC N Engl J Med; 2018 Aug; 379(9):834-845. PubMed ID: 30157398 [TBL] [Abstract][Full Text] [Related]
30. Polio endgame: the global introduction of inactivated polio vaccine. Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843 [TBL] [Abstract][Full Text] [Related]
31. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Thompson KM; Kalkowska DA; Duintjer Tebbens RJ Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673 [TBL] [Abstract][Full Text] [Related]
32. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM Risk Anal; 2021 Feb; 41(2):248-265. PubMed ID: 31960533 [TBL] [Abstract][Full Text] [Related]